Evogene (NASDAQ:EVGN) Now Covered by StockNews.com

StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN) in a report published on Tuesday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Alliance Global Partners restated a “buy” rating on shares of Evogene in a research note on Friday, March 7th.

Evogene Trading Up 8.0%

EVGN opened at $1.22 on Tuesday. The stock’s 50 day simple moving average is $1.21 and its 200-day simple moving average is $1.49. The stock has a market cap of $6.55 million, a PE ratio of -0.27 and a beta of 1.55. Evogene has a 1 year low of $0.95 and a 1 year high of $9.00.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.78. The firm had revenue of $1.61 million for the quarter, compared to analyst estimates of $3.63 million. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%. During the same quarter in the previous year, the firm posted ($1.30) EPS.

Institutional Investors Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Jane Street Group LLC acquired a new position in shares of Evogene Ltd. (NASDAQ:EVGN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 21,345 shares of the biotechnology company’s stock, valued at approximately $40,000. Jane Street Group LLC owned about 0.40% of Evogene at the end of the most recent quarter. Institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.